Figure 2. The tumor clone frequency in skin as predictor of progression-free and overall survival in patients with cutaneous T cell lymphomas.
A. Kaplan-Meier estimates of progression-free (left panel) and overall survival (right) in 208 patients with cutaneous T cell lymphomas in the discovery set, according to the tumor clone frequency in skin (<25% versus >25% of the total T cells in skin). B. Kaplan-Meier estimates of progression-free survival in 101 patients with cutaneous T cell lymphomas in the validation set, according to the tumor clone frequency in skin (<25% versus >25% of the total T cells in skin). C. Kaplan-Meier estimates of progression-free (left panel) and overall survival (right) in 177 patients with mycosis fungoides in the discovery set, according to the tumor clone frequency in skin (<25% versus >25% of the total T cells in skin). D. Kaplan-Meier estimates of progression-free survival in 87 patients with mycosis fungoides in the validation set, according to the tumor clone frequency in skin (<25% versus >25% of the total T cells in skin). p-values in A-D are estimated by Cox univariable analysis. E. Kaplan-Meier estimates of progression-free (left panel) and overall survival (right) in 22 patients with Sézary syndrome in the discovery set, according to the tumor clone frequency in skin (<25% versus >25% of the total T cells in skin).